Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension

Handbook of Experimental Pharmacology

Volumn 218, Issue , 2013, Pages 381-408

  Berghausen, Eva ^a,b   Freyhaus, Henrik Ten ^a,b   Rosenkranz, Stephan ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Imatinib; Plateletderived growth factor; Pulmonary arterial hypertension; Receptor tyrosine kinase; Tyrosine kinase inhibitor

Indexed keywords

AMBRISENTAN; BOSENTAN; ILOPROST; IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR C; PLATELET DERIVED GROWTH FACTOR CC; PLATELET DERIVED GROWTH FACTOR D; PLATELET DERIVED GROWTH FACTOR DD; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROSTACYCLIN; SILDENAFIL; TADALAFIL; TREPROSTINIL; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CATHETER COMPLICATION; CELL SURVIVAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INDUCTION; ENZYME INHIBITION; EXERCISE; FLUSHING; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HUMAN; INJECTION SITE PAIN; LEUKEMIA; LUNG CIRCULATION; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MYELOID LEUKEMIA; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCLERODERMA; SEPSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SUBDURAL HEMATOMA; UPREGULATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION, PULMONARY; PROTEIN KINASE INHIBITORS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84893028696     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-38664-0-16     Document Type: Article

References (141)

1. Abe J, Deguchi J, Takuwa Y et al (1998) Tyrosine phosphorylation of platelet derived growth factor beta receptors in coronary artery lesions: Implications for vascular remodelling after directional coronary atherectomy and unstable angina pectoris. Heart 79:400-406
2. Abe K, Toba M, Alzoubi A, Koubsky K, Ito M, Ota H, Gairhe S, Gerthoffer WT, Fagan KA, McMurtry IF, Oka M (2011) Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mol Biol 45:804-808
3. Arcot SS, Lipke DW, Gillespie MN, Olson JW (1993) Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 46:1086-1091
4. Atallah E, Durand JB, Kantarijan H, Cortes J (2007) Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110:1233-1237
5. Badesch DB, Abman SH, Simonneau G et al (2007) Medical therapy for pulmonary arterial hypertension. Updated ACCP evidence-based clinical practice guidelines. Chest 131:1917-1928
6. Badesch DB, Champion HC, Sanchez MA et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl S):55-66
7. Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, Kinsella JP, Abman SH (2003) Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284:L826-L833
8. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667-2676
9. Barst RJ, Rubin LJ et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296-302
10. Barst RJ, Gibbs SR, Ghofrani HA et al (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl S):S78-S84
11. Baselga J (2006) Targeting tyrosine kinases in cancer: The second wave. Science 312:1175-1178
12. Baumer AT, Ten Freyhaus H, Sauer H et al (2008) PI3 kinase-dependent membrane recruitment of rac-1 and p47phox is critical for alpha PDGF receptor-induced production of reactive oxygen species. J Biol Chem 283:7864-7876
13. Benza RL, Miller DP, Gomberg-Maitland M et al (2010) Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122:164-172
14. Berghausen E, Janssen W, Vantler M, Zimmermann T, ten Freyhaus H, Zhao JJ, Schermuly RT, Rosenkranz S (2011) The PI 3-kinase isoform p110alpha is essential for growth factor-induced vascular remodeling in pulmonary hypertension. Eur Heart J 32(Suppl):3072 (Abstract)
15. Bergsten E, Uutela M, Li X et al (2001) PDGF-D is a specific, protease-activated ligand for the PDGF -receptor. Nat Cell Biol 3:512-516
16. Caglayan E, Vantler M, Leppanen O et al (2011) Disruption of PDGF-dependent PI 3-kinase and PLC activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo. J Am Coll Cardiol 57:2527-2538
17. Cai Y, Han M, Luo L, Song W, Zhou X (1996) Increased expression of pdgf and c-myc genes in lungs and pulmonary arteries of pulmonary hypertensive rats induced by hypoxia. Chin Med Sci J 11:152-156
18. Chen SJ, Chen YF et al (1995) Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79:2122-2131
19. Cheng H, Force T (2010) Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 106:21-34
20. Chockalingam A, Gnanavelu G, Venkatesan S et al (2005) Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 99:91-95
21. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J (1994) PDGF-and insulin-dependent pp70S6K activation mediated by phosphatidylinositol-3-OH- kinase. Nature 370:71-75
22. Cohen MH, Johnson JR, Pazdur R (2005) US Food and Drug Administration drug approval summary: Conversion of imatinib mesylate (sti571; gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 11:12-19
23. D'Alonzo GE, Barst RJ, Ayres SM et al (1991) Survival in patients with primary pulmonary hypertension. Ann Intern Med 115:343-349
24. Dahal BK, Cornitescu T, Tretyn A et al (2010) Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 181:158-167
25. Dahal BK, Heuchel R, Pullamsetti SS, Wilhelm J, Ghofrani HA, Weissmann N, Seeger W, Grimminger F, Schermuly RT (2011a) Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-. Pulm Circ 1:259-268
26. Dahal BK, Kosanovic D, Kaulen C, Cornitescu T, Savai R, Hoffmann J, Reiss I, Ghofrani HA, Weissmann N, Kubler WM, Seeger W, Grimminger F, Schermuly RT (2011b) Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res 12:60
27. Delgado JF, Conde E, Sanchez V et al (2005) Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 7:1011-1016
28. DeMali KA, Whiteford CC, Ulug ET, Kazlauskas A (1997) Platelet-derived growth factordependent cellular transformation requires either phospholipase C or phosphatidylinositol 3 kinase. J Biol Chem 272:9011-9018
29. Druker BJ, Guilhot F, O'Brian SG, IRIS Investigators et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417
30. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S (2011) Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Eur Respir J 38:218-220
31. Falcetti E, Hall SM, Phillips PG et al (2010) Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 182:1161-1170
32. Fambrough D, McClure K, Kazlauskas A, Lander ES (1999) Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell 97:727-741
33. Farber HW, Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med 351:1655-1665
34. Fernandez A, Sanguino A et al (2007) An anticancer c-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 117:4044-4054
35. Galiè N, Ghofrani HA et al (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157
36. Galiè N, Brundage BH et al (2009a) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894-2903
37. Galiè N, Hoeper MM, Humbert M et al (2009b) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493-2537
38. Galiè N, Manes A, Negro L et al (2009c) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30:394-403
39. Galiè N, Palazzini M, Manes A (2010) Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 31:2080-2086
40. Gambaryan N, Perros F, Montani D, Cohen-Kaminski S, Mazmanian GM, Humbert M (2010) Imatinib inhibits bone marrow-derived c-kit+ cell mobilization in hypoxic pulmonary hypertension. Eur Respir J 35:1209-1211
41. Garcia-Hernandez FJ, Castillo-Palma MJ, Gonzalez-Leon R et al (2008) Experience with imatinib to treat pulmonary arterial hypertension. Arch Bronconeumol 44:689-691
42. Ghofrani HA, Seeger W, Grimminger F (2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353:1412-1413
43. Ghofrani HA, Morrell NW, Hoeper MM et al (2010a) Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182:1171-1177
44. Ghofrani HA, Morrell NW, Hoeper MM et al (2010b) Long term use of imatinib in patients with severe pulmonary arterial hypertension. Am J Respir Crit Care Med 181(Suppl):A2513 (Abstract)
45. Gilbertson DG, Duff ME, West JW et al (2001) Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGFandreceptor. J Biol Chem 276:27406-27414
46. Grimminger F, Schermuly RT (2010) PDGF receptor and its antagonists: Role in treatment of PAH. Adv Exp Med Biol 661:435-446
47. Gschwind HP, Pfaar U et al (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503-1512
48. Haga M, Yamashita A et al (2003) Oscillatory shear stress increases smooth muscle cell proliferation and Akt phosphorylation. J Vasc Surg 37:1277-1284
49. Hassoun PM, Mouthon L, Barbera JA et al (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54(Suppl S):S10-S19
50. Haworth SG (2007) The cell and molecular biology of right ventricular dysfunction in pulmonary hypertension. Eur Heart J 28(Suppl H):H10-H16
51. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316
52. Hennigs JK, Keller G, Baumann HJ et al (2011) Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension BMC Pulm Med 11:30
53. Hoeper MM, Barst RJ, Bourge R et al (2011a) Imatinib improves exercise capacity and hemodynamics at 24 weeks as add-on therapy in symptomatic pulmonary arterial hypertension patients: The IMPRES Study. Chest 140(Suppl):1045A (Abstract)
54. Hoeper M, Barst RJ, Galiè N et al (2011b) Imatinib in pulmonary arterial hypertension, a randomized efficacy study (IMPRES). Eur Respir J 38(Suppl):413 (Abstract)
55. Hoeper MM, Barst RJ, Chang HJ et al (2012) Imatinib safety and efficacy: Interim analysis of IMPRES extension study in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 184(Suppl):A2495 (Abstract)
56. Huang Q, Sun R (1997) Changes of PDGF- and receptor gene expression in hypoxic rat pulmonary vessels. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 19:470-473
57. Humar R, Kiefer FN et al (2002) Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16:771-780
58. Humbert M, Monti G, Fartoukh M et al (1998) Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11:554-559
59. Humbert M, Segal ES, Kiely DG et al (2007) Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30:338-340
60. Humbert M, Sitbon O, Chaouat A et al (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122:156-163
61. Izikki M, Guignabert C, Fadel E et al (2009) Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 119:512-523
62. Joly M, Kazlauskas A, Fay FS, Corvera S (1994) Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase sites. Science 263:684-687
63. Jones R, Capen D, Jacobson M, Munn L (2006) PDGF and microvessel wall remodeling in adult rat lung: Imaging PDGF-aa and PDGF-r molecules in progenitor smooth muscle cells developing in experimental pulmonary hypertension. Cell Tissue Res 326:759-769
64. Kappert K, Peters KG, Bohmer FD, Ostman A (2005) Tyrosine phosphatases in vessel wall signaling. Cardiovasc Res 65:587-598
65. Kappert K, Paulsson J, Sparwel J et al (2007) Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. FASEB J 21:523-534
66. Katayose D, Ohe M, Yamauchi K et al (1993) Increased expression of PDGF- and -chain genes in rat lungs with hypoxic pulmonary hypertension. Am J Physiol 264:L100-L106
67. Kazlauskas A (1994) Receptor tyrosine kinases and their targets. Curr Opin Genet Dev 4:5-14
68. Kerkela R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916
69. Klinghoffer RA, Duckworth B, Valius M, Cantley L, Kazlauskas A (1996) Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol Cell Biol 16:5905-5914
70. Kundra V, Escobedo JA, Kazlauskas A et al (1994) Regulation of chemotaxis by the plateletderived growth factor receptor . Nature 367:474-476
71. Kwapiszewska G, Wilhelm J, Wolff S et al (2005) Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. Respir Res 6:109
72. Lanner MC, RaperM et al (2005) Heterotrimeric G proteins and the platelet-derived growth factor receptor-beta contribute to hypoxic proliferation of smooth muscle cells. Am J Respir Cell Mol Biol 33:412-419
73. LaRochelle WJ, Jeffers M, McDonald WF et al (2001) PDGF-D, a new protease-activated growth factor. Nat Cell Biol 3:517-521
74. Le Coutre P, Kreuzer KA et al (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53:313-323
75. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C (1994) Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8:1875-1887
76. Levitzki A (2005) PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 65:581-586
77. Li X, Pontén A, Aase K et al (2000) PDGF-C is a new protease-activated ligand for the PDGF -receptor. Nat Cell Biol 2:302-309
78. Lindahl P, Johansson BR, Leveen P, Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-245
79. Machado R, Eickelberg O, Elliott CG et al (2009) Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl S):S32-S42
80. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A (2009) Reversible dasatinibinduced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 43:967-968
81. McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573-1619
82. Mellgren AM, Smith CL, Olsen GS et al (2008) Platelet-derived growth factor receptor beta signaling is required for efficient epicardial cell migration and development of two distinct coronary vascular smooth muscle cell populations. Circ Res 103:1393-1401
83. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M (2005) Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112:423-431
84. Miyake S, Mullane-Robinson KP, Lill NL, Douillard P, Band H (1999) Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J Biol Chem 274:16619-16628
85. Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jas X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125:2128-2137
86. Montmayeur JP, Valius M, Vandenheede J, Kazlauskas A (1997) The platelet-derived growth factor -receptor triggers multiple cytoplasmic signaling cascades that arrive at the nucleus at distinguishable inputs. J Biol Chem 272:32670-32678
87. Morrell NW, Adnot S, Archer SL et al (2009) Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl S):S20-S31
88. Nagaraj C, Tang B, Bálint Z, Wygrecka M, Hrzenjak A, Kwapiszewska G, Stacher E, Lindenmann J, Weir EK, Olschewski H, Olschewski A (2013) Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 41:85-95
89. Nakamura K, Akagi S, Ogawa A et al (2011) Pro-apoptotic effects of imatinib on PDGFstimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 159(2):100-106
90. Newman JH, Trembath RC et al (2004) Genetic basis of pulmonary arterial hypertension: Current understanding and future directions. J Am Coll Cardiol 43(Suppl S):33S-39S
91. Ogawa A, Firth AL, YaoW et al (2009) Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 297:L666-L676
92. Olschewski H, Simonneau G et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322-329
93. Oudiz RJ, Galie N et al (2009) Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 54:1971-1981
94. Panzhinskiy E, Zawada WM, Stenmark KR, Das M (2012) Hypoxia induces unique proliferative response in adventitial fibroblasts by activating PDGF receptor-JNK1 signalling. Cardiovasc Res 95(3):356-365
95. Patterson KC, Weissmann A, Ahmadi T, Farber HW (2006) Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 145:152-153
96. Peng B, Lloyd P et al (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879-894
97. Perros F, Montani D, Dorfmuller P et al (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178:81-88
98. Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Rosenkranz S, Schermuly RT (2012) Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 32:1354-1365
99. Quinta's-Cardama A, Kantarijan H, O'Brien S et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914
100. Raines EW (2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15:237-254
101. Rasheed W, Flaim B, Seymour JF (2009) Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33:861-864
102. Rosenkranz S (2007) Pulmonary hypertension: Current diagnosis and treatment. Clin Res Cardiol 96:527-541
103. Rosenkranz S, Kazlauskas A (1999) Evidence for distinct signaling properties and biological responses induced by the PDGF receptor and subtypes. Growth Factors 16:201-216
104. Rosenkranz S, DeMali KA, Gelderloos JA, Bazenet C, Kazlauskas A (1999) Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AAdependent chemotaxis and DNA synthesis. J Biol Chem 274:28335-28343
105. Rosenkranz S, Ikuno Y, Leong FL et al (2000) Src family kinases negatively regulate plateletderived growth factor alpha receptor-dependent signaling and disease progression. J Biol Chem 275:9620-9627
106. Rubin LJ, Badesch DB et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903
107. Sato N, Narita M, Takahashi M et al (2003) The effects of STI571 on antigen presentation in dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol 2:67-75
108. Schermuly RT, Dony E, Ghofrani HA et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811-2821
109. Schultz K, Fanburg BL et al (2006) Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol 290: H2528-H2534
110. Schwartz SM (1997) Perspectives series: Cell adhesion in vascular biology: Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 99:2814-2816
111. Shah AM, Campbell P, Peacock A, Barst RJ, Quinn D, Salomon SD, for the IMPRES Investigators (2012) Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with advanced PAH: The Imatinib in Pulmonary arterial hypertension, a Randomized Efficacy Study (IMPRES) echocardiography sub-study. Heart Fail (Abstract)
112. Simonneau G, Barst RJ, Galiè N et al (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800-804
113. Simonneau G, Rubin LJ, Galiè N et al (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med 149:521-530
114. Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(Suppl S):S43-S54
115. Sitbon O, Galiè N (2010) Treat-to-target strategies in pulmonary arterial hypertension: The importance of using multiple goals. Eur Respir Rev 19:272-278
116. Sitbon O, Humbert M, Jais X et al (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105-3111
117. Soriano P (1994) Abnormal kidney development and haematological disorders in PDGF -receptor mutant mice. Genes Dev 8:1888-1896
118. Souza R, Sitbon O, Parent G, Simonneau G, Humbert M (2006) Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61:736
119. Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M (2002) Hypoxic activation of adventitial fibroblasts: Role in vascular remodeling. Chest 122(Suppl 6):326S-334S
120. Sterpetti AV, Cucina A et al (1992) Modulation of arterial smooth muscle cell growth by haemodynamic forces. Eur J Vasc Surg 6:16-20
121. Tallquist MD, Soriano P, Klinghoffer RA (1999) Growth factor signaling pathways in vascular development. Oncogene 18:7917-7932
122. Tallquist MD, Klinghoffer RA, Heuchel R, Mueting-Nelsen PF, Corrin PD, Heldin C-H, Johnson RJ, Soriano P (2000) Retention of PDGFR- function in mice in the absence of phosphatidylinositol 30-kinase and phospholipase C signalling pathways. Genes Dev 14:3179-3190
123. Tanizawa S, Ueda M et al (1996) Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: An immunohistochemical study. Heart 75:549-556
124. Tapper EB, Knowles D, Heffron T et al (2009) Portopulmonary hypertension: Imatinib is a novel tretament and the Emory experience with this condition. Transplant Proc 41:1969-1971
125. Ten Freyhaus H, Huntgeburth M et al (2006) Novel Nox inhibitor VAS2870 attenuates PDGFdependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 71:331-341
126. Ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S (2009) Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 98:265-267
127. Ten Freyhaus H, Dagnell M, Leuchs M et al (2011) Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. Am J Respir Crit Care Med 183:1092-1102
128. Ten Freyhaus H, Janssen W, Leuchs M, Zierden M, Vantler M, Caglayan E, Schermuly RT, Tallquist MD, Rosenkranz S (2012) Disruption of PDGFR-dependent PI3K and PLC signaling protects from hypoxia-induced pulmonary hypertension. Circulation 125(Suppl) (Abstract)
129. Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes J (2010) Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 116:3152-3159
130. Tu L, De Man FS, Girerd B, Huertas A, Chaumais MC, Lecerf F, François C, Perros F, Dorfmuller P, Fadel E, Montani D, Eddahibi S, Humbert M, Guignabert C (2012) A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. Am J Respir Crit Care Med 186(7):666-676
131. Tuder RM, Voelkel N (2010) Pulmonary hypertension and inflammation. J Lab Clin Med 132:16-24
132. Tuder RM, Abman SH, Braun T et al (2009) Development and pathology of pulmonary hypertension. J Am Coll Cardiol 54(Suppl S):S3-S9
133. Valius M, Kazlauskas A (1993) Phospholipase C-1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 73:321-334
134. Valius M, Secrist J-P, Kazlauskas A (1995) The GTPase activating protein of Ras suppresses platelet-derived growth factor beta receptor signaling by silencing phospholipase C-1. Mol Cell Biol 15:3058-3071
135. Van Wolferen SA, Marcus JT, Boonstra A et al (2007) Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 28:1250-1257
136. Vantler M, Caglayan E, Zimmermann WH, Baumer AT, Rosenkranz S (2005) Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 30-kinase is important. J Biol Chem 280:14168-14176
137. Vantler M, Karikkineth BC, Naito H et al (2010) PDGF-BB protects cardiomyocytes from apoptosis and improves contractile function of engineered heart tissue. J Mol Cell Cardiol 48:1316-1323
138. Wharton J, Davie N et al (2000) Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 102:3130-3136
139. Wharton J, Strange JW et al (2005) Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172:105-113
140. Young KC, Torres E, Hehre D, Suguihara C, Hare J (2009) Neonatal c-kit mutant mice exhibit decreased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 120: S750-S751
141. Zhang L, Ma J, Shen T, Wang S, Ma C, Liu Y, Ran Y, Wang L, Liu L, Zhu D (2012) Plateletderived growth factor (PDGF) induces pulmonary vascular remodeling through 15-LO/15-HETE pathway under hypoxic condition. Cell Signal 24:1931-1939